Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Peritonitis | Case report

Resolution of severe eosinophilic peritonitis in a patient on continuous ambulatory peritoneal dialysis by changing from Dianeal peritoneal dialysis solution to Stay-Safe Balance solution: a case report

Authors: Zi Chan, Yun Ho Hui, Sunny Sze Ho Wong

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Eosinophilic peritonitis is a well-known complication at the initiation of peritoneal dialysis. It is often due to an allergic reaction to peritoneal dialysis solution or sometimes to the peritoneal dialysis catheter itself. Most cases are self-limiting with expected spontaneous resolution within a few weeks. Treatment is necessary for severe or persistent cases. However, the optimal treatment has not yet been defined. There have been only a few case reports on the use of anti-histamines and/or steroids for the treatment of eosinophilic peritonitis. We reported a case of severe eosinophilic peritonitis successfully treated by switching the brand of peritoneal dialysis fluid (same glucose concentration). To the best of our knowledge, this is the first reported case employing such a treatment strategy.

Case presentation

An eighty-two-year-old man with end-stage renal failure was started on continuous ambulatory peritoneal dialysis with Dianeal® (Baxter) peritoneal dialysis solution. He developed eosinophilic peritonitis 19 days after initiation of peritoneal dialysis. Infectious causes were ruled out by bacterial, fungal and tuberculosis smears and cultures. In view of the persistent and severe symptoms, we intervened by switching from Dianeal® (Baxter) peritoneal dialysis solution to Stay-Safe Balance® (Fresenius) solution with the same glucose concentration. His eosinophilic peritonitis resolved 5 days after switching the peritoneal dialysis solution.

Conclusion

In severe or persistent cases of eosinophilic peritonitis requiring treatment, other than the use of steroids and anti-histamines, switching to a different brand of peritoneal dialysis solution can be considered.
Literature
1.
go back to reference Oh SY, Kim H, Kang JM, et al. Eosinophilic peritonitis in a patient with continuous ambulatory peritoneal dialysis (CAPD). Korean J Intern Med. 2004;19(2):121–3.CrossRefPubMedPubMedCentral Oh SY, Kim H, Kang JM, et al. Eosinophilic peritonitis in a patient with continuous ambulatory peritoneal dialysis (CAPD). Korean J Intern Med. 2004;19(2):121–3.CrossRefPubMedPubMedCentral
2.
go back to reference Chan MK, Chow L, Lam SS, et al. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study. Am J Kidney Dis. 1988;11:180–3.CrossRefPubMed Chan MK, Chow L, Lam SS, et al. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study. Am J Kidney Dis. 1988;11:180–3.CrossRefPubMed
3.
go back to reference Minato S, Miyazawa H, Kitano T, et al. Eosinophilic peritonitis induced by sucroferric oxyhydroxide. Perit Dial Int. 2020;40(4):419–21.CrossRefPubMed Minato S, Miyazawa H, Kitano T, et al. Eosinophilic peritonitis induced by sucroferric oxyhydroxide. Perit Dial Int. 2020;40(4):419–21.CrossRefPubMed
4.
go back to reference Wang Z, Li Z, Luo S, et al. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review. J Int Med Res. 2021;49(6):030006052110253.CrossRef Wang Z, Li Z, Luo S, et al. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review. J Int Med Res. 2021;49(6):030006052110253.CrossRef
5.
go back to reference Xu Y, Gao C, Xu J, Chen N. Successful Treatment of Idiopathic Eosinophilic Peritonitis by Oral Corticosteroid Therapy in a Continuous Ambulatory Peritoneal Dialysis Patient. Case Rep Nephrol Dial. 2015;5(2):130–4.CrossRefPubMedPubMedCentral Xu Y, Gao C, Xu J, Chen N. Successful Treatment of Idiopathic Eosinophilic Peritonitis by Oral Corticosteroid Therapy in a Continuous Ambulatory Peritoneal Dialysis Patient. Case Rep Nephrol Dial. 2015;5(2):130–4.CrossRefPubMedPubMedCentral
6.
go back to reference Albilali AS, Rahim KA, Edrees BM, Alshaya HO. Resolution of eosinophilic peritonitis with oral prednisolone in a child receiving peritoneal dialysis. Perit Dial Int. 2011;31(3):359–60.CrossRefPubMed Albilali AS, Rahim KA, Edrees BM, Alshaya HO. Resolution of eosinophilic peritonitis with oral prednisolone in a child receiving peritoneal dialysis. Perit Dial Int. 2011;31(3):359–60.CrossRefPubMed
7.
go back to reference Thakur SS, Unikowsky B, Prichard S. Eosinophilic peritonitis in CAPD: treatment with prednisone and diphenhydramine. Perit Dial Int. 1997;17(4):402–3.CrossRefPubMed Thakur SS, Unikowsky B, Prichard S. Eosinophilic peritonitis in CAPD: treatment with prednisone and diphenhydramine. Perit Dial Int. 1997;17(4):402–3.CrossRefPubMed
8.
go back to reference Tang S, Lo CY, Lo WK, Chan TM. Resolution of eosinophilic peritonitis with ketotifen. Am J Kidney Dis. 1997;30(3):433–6.CrossRefPubMed Tang S, Lo CY, Lo WK, Chan TM. Resolution of eosinophilic peritonitis with ketotifen. Am J Kidney Dis. 1997;30(3):433–6.CrossRefPubMed
9.
go back to reference Forbes TA, Lunn AJ. Montelukast: a novel therapeutic option in eosinophilic peritonitis. Pediatr Nephrol. 2014;29(7):1279–82.CrossRefPubMed Forbes TA, Lunn AJ. Montelukast: a novel therapeutic option in eosinophilic peritonitis. Pediatr Nephrol. 2014;29(7):1279–82.CrossRefPubMed
10.
go back to reference Tzvi-behr S, Frishberg Y, Ben-shalom E, Rinat C, Becker-cohen R. Eosinophilia in a peritoneal dialysis patient: Answers. Pediatr Nephrol. 2018;33(9):1507–8.CrossRefPubMed Tzvi-behr S, Frishberg Y, Ben-shalom E, Rinat C, Becker-cohen R. Eosinophilia in a peritoneal dialysis patient: Answers. Pediatr Nephrol. 2018;33(9):1507–8.CrossRefPubMed
11.
go back to reference MacGinley R, Cooney K, Alexander G, Cohen S, Goldsmith DJA. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. American J Kidney Dis. 2002;40(5):1030–5.CrossRef MacGinley R, Cooney K, Alexander G, Cohen S, Goldsmith DJA. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. American J Kidney Dis. 2002;40(5):1030–5.CrossRef
12.
go back to reference Martis L, Patel M, Giertych J, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet. 2005;365(9459):588–94.CrossRefPubMed Martis L, Patel M, Giertych J, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet. 2005;365(9459):588–94.CrossRefPubMed
13.
go back to reference Johnson DW, Brown FG, Clarke M, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int. 2012;32(5):497–506.CrossRefPubMedPubMedCentral Johnson DW, Brown FG, Clarke M, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int. 2012;32(5):497–506.CrossRefPubMedPubMedCentral
14.
go back to reference Cho Y, Johnson DW, Craig JC, Strippoli GFM, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews. 2014;(Issue 3):CD007554. Cho Y, Johnson DW, Craig JC, Strippoli GFM, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews. 2014;(Issue 3):CD007554.
Metadata
Title
Resolution of severe eosinophilic peritonitis in a patient on continuous ambulatory peritoneal dialysis by changing from Dianeal peritoneal dialysis solution to Stay-Safe Balance solution: a case report
Authors
Zi Chan
Yun Ho Hui
Sunny Sze Ho Wong
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02786-8

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.